5WB6

FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(11S)-11-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-6-fluoro-2-oxo-1,3,4,10,11,13-hexahydro-2H-5,9:15,12-di(azeno)-1,13-benzodiazacycloheptadecin-18-yl]carbamate

Summary for 5WB6

• Entry DOI: 10.2210/pdb5wb6/pdb
• Descriptor: Coagulation factor XI, methyl [(11S)-11-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-6-fluoro-2-oxo-1,3,4,10,11,13-hexahydro-2H-5,9:15,12-di(azeno)-1,13-benzodiazacycloheptadecin-18-yl]carbamate, SULFATE ION, ... (5 entities in total)
• Functional Keywords: hydrolase, serine protease, blood coagulation factor, protein inhibitor complex, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
• Biological source: Homo sapiens (Human)
• Cellular location: Secreted: P03951
• Total number of polymer chains: 1
• Total formula weight: 29222.41

Authors

Sheriff, S. (deposition date: 2017-06-28, release date: 2017-08-02, Last modification date: 2024-11-20)

Primary citation

Wang, C.,Corte, J.R.,Rossi, K.A.,Bozarth, J.M.,Wu, Y.,Sheriff, S.,Myers, J.E.,Luettgen, J.M.,Seiffert, D.A.,Wexler, R.R.,Quan, M.L.
Macrocyclic factor XIa inhibitors.
Bioorg. Med. Chem. Lett., 27:4056-4060, 2017

PubMed Abstract: A series of macrocyclic factor XIa (FXIa) inhibitors was designed based on an analysis of the crystal structures of the acyclic phenylimidazole compounds. Further optimization using structure-based design led to inhibitors with pM affinity for FXIa, excellent selectivity against a panel of relevant serine proteases, and good potency in the activated partial thromboplastin time (aPTT) clotting assay.

PubMed: 28780160
DOI: 10.1016/j.bmcl.2017.07.048

Experimental method

X-RAY DIFFRACTION (2.35 Å)